SPOTLIGHT: Is Point finished?

Point Therapeutics is hunkering down into survival mode. The company announced it has reduced its workforce from 33 to eight and will move into temp office space is it scouts a possible sale or bankruptcy. Its lead therapy is the cancer therapy talabostat. Report